GlassScriptPhysician profile
Timothy Earl Raymond
NPI 1760707319
$88,293.34
in general payments reported to CMS, 2019-2025
25 companies · $57K in 2025
The $57K reported for 2025 was more than what 94% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,121 · 2020: $380 · 2021: $671 · 2022: $2,386 · 2023: $1,332 · 2024: $24K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $69K · Consulting Fee: $6,190 · Food and Beverage: $4,462 · Travel and Lodging: $2,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,265.00 |
| Consulting Fee | $6,190.00 |
| Food and Beverage | $4,462.25 |
| Travel and Lodging | $2,819.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $39,247.10 | 2019-2025 | Wainua, Farxiga |
| Bridgebio Pharma, INC. | $32,658.40 | 2025 | Attruby |
| Pfizer INC. | $7,761.12 | 2023-2025 | |
| Abbott Laboratories | $4,051.71 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Mitraclip |
| Alnylam Pharmaceuticals INC. | $1,657.86 | 2022-2024 | Amvuttra, Onpattro |
| Medtronic, INC. | $907.14 | 2022-2023 | Reveal Linq |
| Medtronic Vascular, INC. | $522.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $237.62 | 2019-2022 | |
| Biotronik INC. | $187.76 | 2022-2023 | Orsiro Mission, Pk Papyrus, Recross |
| Abiomed | $170.62 | 2020-2025 | |
| Atricure, INC. | $157.56 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Cvrx, INC. | $153.36 | 2023 | Barostim Neo System |
| Briohealth Solutions, INC. | $148.49 | 2025 | Briovad |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.78 | 2021-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $74.52 | 2023-2025 | Verquvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endotronix, INC. | $65.80 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Amgen INC. | $57.71 | 2021-2025 | Repatha |
| Nuwellis, INC. | $40.65 | 2019 | |
| Scpharmaceuticals INC. | $19.01 | 2023 | |
| Amarin Pharma, INC. | $16.22 | 2021 | |
| Chiesi USA, INC. | $15.95 | 2023 | Kengreal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.50 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $11.09 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Raymond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.